Elsevier

Brain Research

Volume 1003, Issues 1–2, 2 April 2004, Pages 61-67
Brain Research

Research report
Evidence for the involvement of metabotropic glutamatergic, neurokinin 1 receptor pathways and protein kinase C in the antinociceptive effect of dipyrone in mice

https://doi.org/10.1016/j.brainres.2003.11.075Get rights and content

Abstract

This study aimed to investigate further the mechanisms involved in the antinociception caused by dipyrone, given by intraperitoneal (i.p.) or intrathecal (i.t.) routes. The intraperitoneal administration of dipyrone to mice 30 min prior resulted in a significant and dose-related inhibition of the biting responses induced by i.t. injection of glutamate, trans-ACPD or substance P (SP). In addition, dipyrone given by i.t. route, 15 min before glutamate, trans-ACPD or SP, also produced a significant reduction in their nociceptive effects. In addition, dipyrone given by i.t. route, 15 min before glutamate, trans-ACPD or SP, also produced a significant reduction in their nociceptive effects. Dipyrone, given either systemically (i.p.) or by i.t. route also caused a dose-dependent inhibition of phorbol myristate acetate (PMA)-induced nociception. Given by systemic route, dipyrone inhibited PMA-induced paw oedema formation. Collectively, these results extend previous data from our group indicating that glutamatergic-mediated pain responses, specifically those mediated by metabotropic receptor subtype, together with inhibition of neurokinin NK1-mediated response, account for the antinociceptive action of dipyrone in mice. Furthermore, we have also produced experimental evidence indicating that the activation of the protein kinase C-dependent pathway plays a role in the dipyrone antinociceptive action.

Introduction

Dipyrone (metamizol), a pirazolone derivative classified as a non-steroidal anti-inflammatory agent, is widely used in most countries as an antipyretic and analgesic drug. Recently, Chandrasekharan et al. [13] proposed that dipyrone could act through a newly defined mechanism via interaction with COX-3, a cyclooxygenase-1 variant that is abundant in cerebral cortex. However, despite many experimental results [1], [4], [15], [16], [19], [20], [24], [25], [31], [42], [48] taken as evidence of nociception, the precise mechanism through which dipyrone exerts these clinically relevant actions remains uncertain.

Data from our laboratory have shown that dipyrone elicits significant and dose-related spinal and supraspinal antinociception when assessed against formalin, capsaicin and glutamate-induced nociception in mice [4]. The mechanism associated with the antinociceptive action of dipyrone does not seem to be related to its interaction with opioids, GABAB or serotonin receptors, ATP-sensitive potassium channels, nitric oxide or G proteins sensitive to pertussis toxin [4]. Besides antagonising glutamate-induced pain, dipyrone partly inhibited glutamate binding sites in brain cortex [4]. Recently, Ortiz et al. [34] confirmed the absence of involvement of ATP-sensitive K+ channels in dipyrone antinociception, but reported that two blockers of the large and small-conductance-calcium-activated K+ channels, apamin and charybdotoxin, dose-dependently blocked dipyrone-induced antinociception in the formalin test. In contrast, Alves and Duarte [3] found that glibenclamide, an ATP-sensitive K+ channel blocker, but not apamin or charybdotoxin, injected into the paw, was capable of inhibiting the antinociception caused by i.pl. injection of dipyrone against prostaglandin E2-induced hyperalgesia. Thus, depending on the model used to induce nociception and on the route of administration, different mechanisms seem to be involved in the antinociceptive action of dipyrone in rodents.

Glutamatergic receptors are widespread in the central nervous system and are divided into two major types, ionotropic (coupled to membrane ion channels) and metabotropic (mGluRs, coupled to G proteins). Recent evidence obtained using glutamatergic-selective receptor agonists and antagonists indicates that all the subtypes of ionotropic (N-methyl-d-aspartate (NMDA), α-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid (AMPA) and kainate) and metabotropic (groups I, II and III) glutamatergic receptors play relevant roles in the establishment or maintenance of painful states, either in acute or chronic nociception [32], [40], [41], [49] (for review, see Ref. [9]). Furthermore, evidence also suggests that glutamate and some neuropeptides, especially substance P (SP), co-exist in both large and small diameter peripheral sensory fibres [14], [43], [46]. In addition, SP increases the glutamate-induced nociception [10] and the two neurotransmiters can act synergistically in the transmission of pain [5], [26], [38], [45].

In the present study, we sought to examine further the mechanisms through which dipyrone causes antinociception in mice. For this purpose we used selective glutamatergic receptor agonists, substance P and a direct activator of protein kinase C (PKC).

Section snippets

Animals

Male Swiss mice (25–35 g) were used, housed at 22±2 °C under a 12:12-h light/dark cycle and with access to food and water ad libitum. Experiments were performed during the light phase of the cycle. Animals were acclimatised to the laboratory for at least 1 h before testing and were used once during the experiments. Experiments reported in this study were carried out in accordance with current guidelines for the care of laboratory animals and ethical guidelines for investigation of experimental

Effect of dipyrone on spinal excitatory amino acids (EAAs)- or substance P (SP)-induced biting response

Fig. 1A and B shows that dipyrone (15–500 mg/kg), given i.p., 30 min prior resulted in a significant and dose-related inhibition of the biting responses to glutamate (175 nmol/site, i.t.) or trans-ACPD (2.6 nmol/site, i.t.). The inhibition observed was 41.8±15.4% and 80.8±4.3%, respectively. The calculated mean ID50 value for the antinociceptive effect of dipyrone against trans-ACPD-induced biting was 29.2 (22.8–37.4) mg/kg. Given by i.p. route, dipyrone (60–180 mg/kg) also inhibited by

Discussion

The results of the present study extend previous data from our group [4], suggesting that the glutamatergic system plays a critical role in the peripheral and spinal mechanisms through which dipyrone exerts its antinociceptive action in mice. By using selective glutamate receptor agonists we have confirmed previous data from the literature showing that intrathecal administration of trans-ACPD (2.6 nmol/i.t.), kainate (110 pmol/i.t.), AMPA (135 pmol/i.t.) and NMDA (450 pmol/i.t.) results in

Acknowledgements

This study was supported by grants from the Conselho Nacional de Desenvolvimento Cientı́fico e Tecnológico (CNPq), Financiadora de Estudos e Projetos (FINEP), and Programa de Apoio aos Núcleos de Excelência (PRONEX), Brazil. J.S. Siebel is an undergraduate Pharmacy student and she thanks CNPq for support in the form of a studentship.

References (53)

  • I.D. Duarte et al.

    Analgesia by direct antagonism of nociceptor sensitization involves the arginine–nitric oxide–cGMP pathway

    Eur. J. Pharmacol.

    (1992)
  • K. Fisher et al.

    The contribution of metabotropic glutamate receptors (mGluRs) to formalin-induced nociception

    Pain

    (1996)
  • V. Granados-Soto et al.

    Evidence for the involvement of nitric oxide in the antinociceptive effect of ketorolac

    Eur. J. Pharmacol.

    (1995)
  • N. Hernandez et al.

    Antinociception induced by PAG-microinjected dipyrone (metamizol) in rats: involvement of spinal endogenous opioids

    Brain Res.

    (2001)
  • J.K.L. Hylden et al.

    Intrathecal morphine in mice: a new technique

    Eur. J. Pharmacol.

    (1980)
  • S.G. Khasar et al.

    A novel nociceptor signaling pathway revealed in protein kinase C epsilon mutant mice

    Neuron

    (1999)
  • B.B. Lorenzetti et al.

    Mode of analgesic action of dipyrone: direct antagonism of inflammatory hyperalgesia

    Eur. J. Pharmacol.

    (1985)
  • J. Mao et al.

    Increases in protein kinase C gamma immunoreactivity in the spinal cord dorsal horn of rats with painful mononeuropathy

    Neurosci. Lett.

    (1995)
  • J. Mazario et al.

    Antinociceptive effects of metamizol (dipyrone) in rat single motor units

    Neurosci. Lett.

    (1999)
  • V. Neugebauer

    Peripheral metabotropic glutamate receptors: fight the pain where it hurts

    Trends Neurosci.

    (2001)
  • V. Neugebauer et al.

    The involvement of N-methyl-d-aspartate (NMDA) and non-NMDA receptors in the responsiveness of rat spinal neurons with input from the chronically inflamed ankle

    Neurosci. Lett.

    (1994)
  • M.I. Ortiz et al.

    Possible involvement of potassium channels in peripheral antinociception induced by metamizol: lack of participation of ATP-sensitive K+ channels

    Pharmacol. Biochem. Behav.

    (2003)
  • M. Ohsawa et al.

    Involvement of spinal protein kinase C in thermal hyperalgesia evoked by partial sciatic nerve ligation, but not by inflammation in the mouse

    Eur. J. Pharmacol.

    (2000)
  • M. Ohsawa et al.

    Reduced hyperalgesia induced by nerve injury, but not by inflammation in mice lacking protein kinase C gamma isoform

    Eur. J. Pharmacol.

    (2001)
  • J. Palecek et al.

    The effect of phorbol esters on spinal cord amino acid concentrations and responsiveness of rats to mechanical and thermal stimuli

    Pain

    (1999)
  • K.I. Rusin et al.

    Interactions between excitatory amino acids and tachykinins in the rat spinal dorsal horn

    Brain Res. Bull.

    (1993)
  • Cited by (37)

    • Screening for physical and behavioral dependence on non-opioid analgesics in a German elderly hospital population

      2019, Addictive Behaviors
      Citation Excerpt :

      However, the wide distribution of metamizole in Germany and the easiness to obtain this NOA in our country (Glaeske & Hoffmann, 2014) might have obscured those cases. In addition to the aforementioned pharmacodynamics properties, metamizole was found to dampen glutamate-induced hyperalgesia (sensitization to pain) in mice which involved the metabotropic receptor subtype (Beirith, Santos, Rodrigues, Creczynski-Pasa, & Calixto, 1998; Siebel, Beirith, & Calixto, 2004). This is interesting because the sensitization to drug cues and associations of drug-use with environmental (external) cues were considered to be primarily driven by the repeated stimulation of non-NMDA glutamate receptors in key regions of the MDS, more precisely, by the repeated activation of the AMPA- and metabotropic glutamate receptors (Scofield et al., 2016; Spiga, Mulas, Piras, & Diana, 2014).

    • N-demethylation of N-methyl-4-aminoantipyrine, the main metabolite of metamizole

      2018, European Journal of Pharmaceutical Sciences
      Citation Excerpt :

      However, while the analgesic effect of metamizole is similar to indomethacin, its anti-inflammatory effect is weaker (Tatsuo et al., 1994), suggesting also COX-independent pathways. Multiple additional modes of action have been proposed, among them interaction with the adrenergic nervous system (Silva et al., 2015), modulation of potassium channels (Alves and Duarte, 2002; Duarte et al., 1992; Ortiz et al., 2003), stimulation of the endogenous opioid system (Tortorici et al., 1996; Vanegas et al., 1997; Vasquez and Vanegas, 2000), and interaction with glutamate transmission (Beirith et al., 1998; Siebel et al., 2004) or with the endocannabinoid system (Escobar et al., 2012; Maione et al., 2015). The spasmolytic effect of metamizole is experimentally established, but the mechanism is also not fully clarified.

    • Citral: A monoterpene with prophylactic and therapeutic anti-nociceptive effects in experimental models of acute and chronic pain

      2014, European Journal of Pharmacology
      Citation Excerpt :

      To obtain data that were purely derived from the treatment, the inhibition values are presented as the difference between the basal values of vehicle or drug-treated animals and the respective controls. We investigated whether citral could antagonise the nociceptive response elicited by glutamate (a non-selective activator of glutamate receptors) (Beirith et al., 2002), capsaicin (an activator of the TRPV1 channel) (Sakurada et al., 1992), and phorbol 12-myristate 13-acetate (PMA, an activator of protein kinase C) (Siebel et al., 2004) in the mouse paw. The animals used were individually adapted to a 20-cm glass cylinder.

    • Antinociception of β-d-glucan from Pleurotus pulmonarius is possibly related to protein kinase C inhibition

      2012, International Journal of Biological Macromolecules
      Citation Excerpt :

      injection of PMA (500 pmol/paw), an activator of PKC. In such experiments, only the licking time accumulated 15–45 min following injection was recorded [23]. Control animals received vehicle (saline, 10 ml/kg i.p.).

    View all citing articles on Scopus
    View full text